This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Menu
Close
Required prior to initiation of treatment
FOR ALL PATIENTS1
*For example, second-degree (Mobitz type I) atrioventricular block, myocardial infarction and heart failure.1
†Cardiologist advice should be obtained before initiation of VELSIPITY in the following patients to determine overall benefit risk and the most appropriate monitoring:1 In patients with significant QT prolongation (QTcF ≥450 msec in males, ≥470 msec in females);1 in patients with arrhythmias requiring treatment with Class Ia or Class III anti-arrhythmic drugs;1 in patients with unstable ischaemic heart disease, history of cardiac arrest, cerebrovascular disease (occurring more than 6 months prior to treatment initiation) or uncontrolled hypertension;1 in patients with history of symptomatic bradycardia, recurrent cardiogenic syncope or severe untreated sleep apnoea.1
FOR SELECTED PATIENTS1
Example
PfizerPro provides a wealth of VELSIPITY resources to support both patients and healthcare providers.
PP-V1A-GBR-0022 September 2024
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024